An evidence-based workflow for integrating molecular testing with histopathology in the workup of meningiomas

Clicks: 26
ID: 330799
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #83 of 287 articles by views in journal of neuro-oncology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 287 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Meningiomas are graded using histologic and molecular criteria according to the World Health Organization (WHO) classification. However, there is scant evidence considering the specific value of each individual atypical histological feature that contributes to WHO grading. There is also little evidence-based guidance as to which cases should receive molecular testing. Methods Detailed histological information was collected for 1058 resected meningiomas, including cases with genomic DNA methylation and copy number variant (CNV) data, next-generation sequencing, and RNA risk score. Integrated analyses were conducted using known prognostic variables, including WHO Grade, Ki-67, mitotic index (MI), and atypical histologic features (necrosis, hypercellularity, macronucleoli, sheeting, and small cells). Results Necrosis, elevated MI, and increased WHO grade correlated with specific DNA methylation patterns, RNA risk groups, and chromosomal CNVs. Predictive analysis identified MI as the strongest single correlate, and suggested the presence of ≥ 2 atypical features as an optimal threshold for recurrence prediction. Sheeting architecture was the only independent histologic correlate of recurrence. Integration of histologic and molecular features suggests that tumors with high MI have poor prognosis regardless of molecular profile. Further analysis of low MI tumors revealed specific predictors of unfavorable molecular profiles. Conclusions These data indicate that some atypical histopathologic features are more powerful than others, and can be used on initial screening to increase the yield of molecular profiling of meningiomas. Furthermore, we propose that molecular testing may actually have greatest added value in cases with low, not high, MI.
Reference Key
openalex_W7215091769 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Harrshavasan T. S. Congivaram, Vineeth M. Thirunavu, Lucas Santana‐Santos, Pouya Jamshidi, Jared T Arendhsen, Rudolph J. Castellani, Daniel Jay Brat, Lee Cooper, Marina A. Ayad, William C Chen, Khizar Rehan Nandoliya, Rahul Kishore Chaliparambil, Rishi Jain, Mateo Gomez, Drew Duckett, Madina Jh. Sukhanova, Heather Smith, Matthew McCord, Alicia Steffens, Jordain P. Walshon, Kathleen McCortney, Wenxia Wang, Xinyan Lu, Amy B. Heimberger, David Ronan Raleigh, Stephen T. Magill, Mark W. Youngblood, Craig Horbinski
Are you one of these authors? Claim your profile
Journal journal of neuro-oncology
Year 2026
DOI
10.1093/neuonc/noag217
URL
https://doi.org/10.1093/neuonc/noag217
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.